HIV1 p24 Recombinant Rabbit Monoclonal Antibody [PS01-35]
cat.: HA721527
| Product Type: | Recombinant Rabbit monoclonal IgG, primary antibodies |
|---|---|
| Species reactivity: | HIV1 |
| Applications: | ELISA(Cap) |
| Clonality: | Monoclonal |
| Clone number: | PS01-35 |
| Form: | Liquid |
| Storage condition: | Store at +4℃ after thawing. Aliquot store at -20℃. Avoid repeated freeze / thaw cycles. |
| Storage buffer: | PBS (pH7.4). |
| Concentration: | 1ug/ul |
| Purification: | Protein A affinity purified. |
| Isotype: | IgG |
| Immunogen: | Recombinant protein within HIV1 p24 protein aa 133-363. |
| Positive control: | Recombanint HIV1 p24 protein. |
| Subcellular location: | Virion. |
| Recommended Dilutions:
ELISA(Cap) |
1-2ug/ml |
| Uniprot #: | SwissProt: P12497 HIV1 |
| Alternative names: | CA Capsid protein p24 HIV-1 Gag p24 HIV1gp1 Human immunodeficiency virus 1 Human immunodeficiency virus type 1 p24 |
Images
|
Fig1:
Advantages of Using rAbs： Increased Reproducibility Because recombinant antibody production involves sequencing the antibody light and heavy chains, recombinant antibody production allows researchers more control over the antigen. Ease of Scalability and Continuous Supply In vitro methods for producing antibodies are amenable to large-scale production, meaning antibody availability is unlikely to become a limiting factor. Recombinant antibodies can be produced in weeks as opposed to months. Animal-Free Tech Once the antibody-producing genes are isolated, high-throughput in vitro manufacture can be implemented. This eliminates the numerous ethical and animal welfare concerns commonly associated with traditional monoclonal antibody production. |
Note: All products are “FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE”.